Cargando cotizaciones...
Previsión
No hay datos de analistas disponibles para esta empresa.
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
Carl Zeiss expands presence in South Korea and sees Asia as core market
At the Asia-Pacific summit in Seoul, Carl Zeiss CEO Andreas Pecher emphasized that Zeiss is expanding its innovation and market proximity in South Korea and recently opened a new research center to better serve customers like Samsung and SK Hynix. Corporate leaders are calling for a more pragmatic German industrial policy as value chains diversify amid the AI boom and geopolitical tensions. Many companies still view China as an important market but also see opportunities in South Korea, ASEAN countries and India; at the same time managers warn that Germany’s relative cost and growth disadvantages make investment more difficult. » Más en faz.net
Carl Zeiss launches cost-cutting program and steps up innovation drive
Under CEO Andreas Pecher, Carl Zeiss is consolidating an ambitious cost-cutting program with annual savings of “several hundred million” over three years to free up funds for the innovation program “Beyond.” The focus remains the semiconductor division, supplying high-end projection optics for ASML, while the group is also seeking new future fields such as spatial biology, photonics and precision farming. Restructuring measures include divestments (e.g., sports optics) and staffing adjustments; up to 700 jobs worldwide in the medical technology unit could be affected. The goal is to make Zeiss grow profitably in the long term and to provide resources for scalable, market-ready innovations. » Más en faz.net
Carl Zeiss Meditec: Bronwyn Brophy O'Connor to become CEO on December 1
Bronwyn Brophy O'Connor will succeed Andreas Pecher as CEO of Carl Zeiss Meditec on December 1. At the same time she will join the management board of the parent company and take responsibility for its medical technology division. The executive previously worked at Vitrolife, brings more than 25 years of industry experience and has worked for Thermo Fisher and Medtronic, among others; Pecher had recently launched a cost‑saving program that could cut up to 1,000 jobs. » Más en wiwo.de
Carl Zeiss Meditec defends 200-day line after downgrade by Goldman Sachs
After a sell recommendation from Goldman Sachs, Carl Zeiss Meditec’s stock came under pressure and fell intraday by as much as around 7 percent, but remained just above the 200-day line at €28.98 and later reduced the loss to about 2 percent. Goldman Sachs justified the downgrade with further deteriorated sales prospects and the assessment that these risks were not yet sufficiently reflected in the valuation. The stock is down more than 20 percent year-to-date. » Más en finanzen.net
Carl Zeiss Meditec receives FDA 510(k) clearance for cloud-based ophthalmology software
Carl Zeiss Meditec has received 510(k) clearance from the US FDA for ZEISS CLINIC 360, a cloud- and browser-based software that consolidates diagnostic imaging data, EMR, and practice management systems into a unified patient view. The solution integrates data from ZEISS devices and DICOM-capable third-party devices and offers tools for monitoring glaucoma progression, trend analysis, and case/report exchange via “ZEISS Collaborative Care.” ZEISS CLINIC 360 will be available by subscription in the US from early fall 2026; ZEISS FORUM will remain available for users who prefer on-premise solutions. The product is not approved for use in humans in the EU. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasDatos financieros de la empresa
| (EUR) | junio de 2026 | YoY |
|---|---|---|
| Ingresos | 562,72 M | 2,38 % |
| Beneficio bruto | 302,28 M | 4,34 % |
| Beneficio neto | 55,03 M | 93,94 % |
| EBITDA | 74,87 M | 57,11 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 3018,24 M € |
Número de acciones | 87,54 M |
Máximo/mínimo de 52 semanas | 46,54 € - 22,62 € |
Rentabilidad por dividendo | 1,56 % |
Dividendos TTM | 0,55 € |
Beta | 1,35 |
Ratio P/E | 20,65 |
Ratio PEG | -5,95 |
Ratio P/B | 1,41 |
Ratio P/S | 1,14 |
Perfil de la empresa
Carl Zeiss Meditec AG opera como empresa de tecnología médica en Alemania, el resto de Europa, Estados Unidos, Asia y a nivel internacional. Opera en dos segmentos, Dispositivos Oftálmicos y Microcirugía. El segmento de Dispositivos Oftálmicos ofrece productos y soluciones para el diagnóstico y tratamiento de enfermedades oculares, así como sistemas y consumibles para cirugías de cataratas, retina y refractivas. Atiende a oftalmólogos y optometristas en ejercicio, así como a médicos y cirujanos de hospitales y centros de cirugía ambulatoria. El segmento de Microcirugía ofrece soluciones de visualización para tratamientos quirúrgicos invasivos, y soluciones en el área de otorrinolaringología, cirugía plástica y reconstructiva, odontología y cirugía espinal. Atiende a médicos de diversas especialidades y a hospitales. La empresa fue fundada en 1846 y tiene su sede en Jena, Alemania. Carl Zeiss Meditec AG es una filial de Carl Zeiss AG.
| Nombre | Carl Zeiss Meditec |
| CEO | Andreas Pecher |
| Sede | Jena,
th Alemania |
| Sitio web | |
| Sector | Salud |
| Industria | Proveedores y servicios sanitarios |
| Salida a bolsa | 22/03/2000 |
| Empleados | 5784 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
XETRA | AFX.DE |
Pnk | CZMWF |
Frankfurt | AFX.F |
Düsseldorf | AFX.DU |
Hamburg | AFX.HM |
Milan | 1AFX.MI |
London | 0DHC.L |
SIX | AFX.SW |
München | AFX.MU |
Wien | AFX.VI |